Cortagen

Cortagen is a short synthetic peptide belonging to the family of peptide bioregulators, or cytogens, developed at the St. Petersburg Institute of Bioregulation and Gerontology under the direction of Vladimir Khavinson. Its sequence is the tetrapeptide Ala-Glu-Asp-Pro, and it was obtained by directed synthesis based on the amino acid analysis of Cortexin, a natural peptide preparation extracted from the cerebral cortex ^[1][2]. Like other members of this family, such as Epithalon, Vilon, and Livagen, Cortagen was conceived as a tissue-specific regulator: a very small molecule intended to normalize the function of the organ from whose extract its parent peptide complex was derived.

The research literature on Cortagen centers on the nervous system. In humans it has been reported to aid the structural and functional recovery of peripheral nerve tissue after injury, and animal work has examined its effects on nerve regeneration, gene expression, and tissue culture growth ^[1][2]. In organotypic culture, Cortagen stimulated the growth of explants from the brain cortex while showing the tissue selectivity characteristic of the cytogen class ^[3][6]. Screening studies of short peptides have also probed effects on immune cells and chromatin, where Cortagen behaves distinctly from immune-directed peptides, underscoring its comparative specificity for neural tissue ^[4][5].

Cortagen is not an approved pharmaceutical in Western markets and is not a dietary supplement; it originates in Russian gerontological research and circulates internationally as a research peptide, typically supplied as a lyophilized powder for reconstitution. It is most often discussed alongside the other Khavinson bioregulators within longevity and tissue-recovery protocols, where it is positioned as a targeted, low-burden addition rather than a standalone therapy.

Cortagen is a short peptide bioregulator marketed for nerve and tissue recovery; human safety data are very limited, drawn mainly from small Russian studies, and it is sold as a research chemical. Its risks, long-term effects and drug interactions are not characterized, and considerations are inferred from its peptide class rather than robust clinical evidence.

Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro) developed within the Russian peptide bioregulator program led by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It belongs to the family of short synthetic cytogens designed to reproduce the tissue-directed activity of natural peptide complexes, in this case peptides associated with the brain cortex. Research on Cortagen dates chiefly to the late 1990s and early 2000s, including controlled animal experiments on peripheral nerve regeneration published in the Russian physiological literature. Much of its development and clinical use has taken place within Russia, and the compound is representative of the broader Khavinson bioregulator approach rather than a widely registered international medicine.

Within the peptide and longevity community Cortagen is well regarded as a focused, clearly defined neuro-directed bioregulator, appreciated for the specificity of its proposed action rather than broad, indiscriminate stimulation. It draws particular interest for its reported ability to accelerate peripheral nerve repair and for the intriguing idea, developed across the Khavinson program, that ultra-short peptides can act as gene regulators that nudge tissue back toward a youthful pattern of protein synthesis.

Its tissue selectivity, preferentially supporting neural explants over unrelated cell types, is frequently cited as a point in its favor. Candor is warranted: the supporting evidence comes largely from animal studies and Russian-language sources, with limited independent international replication, so its human benefits remain modestly documented. It is a well-characterized research peptide with a specific neural focus.